|
|
One Tower Bridge, 100 Front Street, Suite 1325, West
Conshohocken, PA 19428 USA
phone:(610) 825-4547
fax:(610) 825-3936
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.zelostherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatments for osteoporosis, psoriasis and other diseases. |
|
| Management |
| Brian MacDonald, M.B., Ch.B., Ph.D., Chief Executive Officer; David Krause, M.D., Senior Vice President and Head of R&D Chief Medical Officer; Alan S. Roemer, Chief Financial Officer |
| |
|
|
| |
|
| Keywords |
| Osteoporosis, Fracture repair, Spine fusion, Renal bone disease, Ostabolin, Forteo |
|
|
|
| Description |
|
Zelos Therapeutics is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. |
|
| Products / Services |
Zelos' lead program, injectable Ostabolin-C for the treatment of osteoporosis, completed a series of three Phase I trials in Canada in 2004-05 and began Phase II testing at hospital and clinic sites in Canada and the USA. The second program, Ostabolin-C gel for topical treatment of psoriasis, began Phase I safety testing in humans this year at sites in the USA.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members